AU2003224725A1 - Hiv therapeutic - Google Patents

Hiv therapeutic

Info

Publication number
AU2003224725A1
AU2003224725A1 AU2003224725A AU2003224725A AU2003224725A1 AU 2003224725 A1 AU2003224725 A1 AU 2003224725A1 AU 2003224725 A AU2003224725 A AU 2003224725A AU 2003224725 A AU2003224725 A AU 2003224725A AU 2003224725 A1 AU2003224725 A1 AU 2003224725A1
Authority
AU
Australia
Prior art keywords
hiv therapeutic
hiv
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003224725A
Other languages
English (en)
Other versions
AU2003224725A8 (en
Inventor
Paul J. Beresford
Judy Lieberman
Michael F. Murray
Carl D. Novina
Phillip A. Sharp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Immune Disease Institute Inc filed Critical Massachusetts Institute of Technology
Publication of AU2003224725A8 publication Critical patent/AU2003224725A8/xx
Publication of AU2003224725A1 publication Critical patent/AU2003224725A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003224725A 2002-03-20 2003-03-20 Hiv therapeutic Abandoned AU2003224725A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36592502P 2002-03-20 2002-03-20
US60/365,925 2002-03-20
US39604102P 2002-07-15 2002-07-15
US60/396,041 2002-07-15
PCT/US2003/008653 WO2003079757A2 (en) 2002-03-20 2003-03-20 Hiv therapeutic

Publications (2)

Publication Number Publication Date
AU2003224725A8 AU2003224725A8 (en) 2003-10-08
AU2003224725A1 true AU2003224725A1 (en) 2003-10-08

Family

ID=28457122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003224725A Abandoned AU2003224725A1 (en) 2002-03-20 2003-03-20 Hiv therapeutic

Country Status (6)

Country Link
US (1) US20040248296A1 (enExample)
EP (1) EP1495141A4 (enExample)
JP (1) JP2005521393A (enExample)
AU (1) AU2003224725A1 (enExample)
CA (1) CA2479530A1 (enExample)
WO (1) WO2003079757A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US8729036B2 (en) * 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
EP2000160A3 (en) * 2002-10-30 2009-03-11 Gambro Lundia AB Method and apparatuses for determining the efficiency of dialysis
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US20040191905A1 (en) * 2002-11-22 2004-09-30 University Of Massachusetts Modulation of HIV replication by RNA interference
EP1590002A4 (en) * 2003-01-17 2007-02-28 Univ Florida siRNA GENE THERAPY
JP2006526394A (ja) * 2003-06-03 2006-11-24 ベニテック オーストラリア リミテッド 二本鎖核酸
WO2005012483A2 (en) * 2003-08-01 2005-02-10 International Therapeutics, Inc. Vpr selective rnai agents and methods for using the same
CA2539256C (en) * 2003-09-17 2012-04-24 Let There Be Hope Medical Research Institute Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells
BRPI0415646A (pt) * 2003-10-22 2006-12-12 Aventis Pharma Inc vetores retrovirais para o suprimento de rna de interferência
KR101246862B1 (ko) * 2004-03-05 2013-03-27 베니텍 리미티드 ＲＮＡｉ 제제의 동시 전달을 위한 다중 프로모터 발현카세트
WO2005089287A2 (en) 2004-03-15 2005-09-29 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1789447B1 (en) 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
EP1796732B1 (en) 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
JP4131271B2 (ja) * 2005-03-30 2008-08-13 ソニー株式会社 情報処理装置および方法、並びにプログラム
ES2366227T3 (es) 2005-11-17 2011-10-18 TET Systems GmbH & Co. KG Sistemas de expresión inducibles.
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ592159A (en) 2005-12-09 2012-12-21 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
EP2231176A2 (en) * 2007-12-14 2010-09-29 The Brigham and Women's Hospital, Inc. Treatment and prevention of hiv infection
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US8728458B2 (en) 2009-04-30 2014-05-20 The Regents Of The University Of California Combination anti-HIV vectors, targeting vectors, and methods of use
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
EP2646466B1 (en) 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
CN105899663B (zh) 2013-12-26 2019-07-26 学校法人东京医科大学 用于基因表达控制的人工模拟miRNA及其用途
CN106068324B (zh) 2013-12-27 2020-12-29 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
WO2018009246A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
JP2022506515A (ja) 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 制御性ｒｎａを発現させるためのベクターシステム

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866701A (en) * 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5714320A (en) * 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
JPH08510134A (ja) * 1993-05-17 1996-10-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｉｖ感染およびエイズを対象としたリボザイム遺伝子治療
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
ATE439041T1 (de) * 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference

Also Published As

Publication number Publication date
CA2479530A1 (en) 2003-10-02
WO2003079757A2 (en) 2003-10-02
WO2003079757A3 (en) 2004-07-08
AU2003224725A8 (en) 2003-10-08
JP2005521393A (ja) 2005-07-21
EP1495141A4 (en) 2006-03-22
US20040248296A1 (en) 2004-12-09
EP1495141A2 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
AU2003224725A1 (en) Hiv therapeutic
AU2002365120A1 (en) Medicaments
AU2003295763A1 (en) Medical devices
AU2003220647A1 (en) Medical devices
AU2003256378A1 (en) Therapeutic pack
AU2002327620A1 (en) Defibrillators
AU2002952384A0 (en) Structures
AU2003255831A1 (en) Delayed-gelation solution
AU2003215209A1 (en) Syringe
AU2003276447A1 (en) Inhalers
AU2002253039A1 (en) Tramadol-based medicament
AU2003259457A1 (en) Auto-destructible syringe
AU2003279911A1 (en) Therapeutic formulations
AU2003294318A1 (en) Therapeutic bioconjugates
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003230395A1 (en) Micro-support structures
AU2003301850A1 (en) Hiv vaccine
AU2003247005A1 (en) Therapy combination
AU2003285320A1 (en) Vaccine
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2002319650A1 (en) Defibrillators
AU2003282722A1 (en) Therapeutic compositions
AU2003215150A1 (en) Therapeutic compounds
AU2003282437A1 (en) Crutch
AU2002335667A1 (en) Modified reoviral therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase